QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
NASDAQ:PASG

Passage Bio - PASG Stock Forecast, Price & News

$1.53
0.00 (0.00%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.30
▼
$1.54
50-Day Range
$1.06
▼
$1.88
52-Week Range
$1.04
▼
$5.33
Volume
270,153 shs
Average Volume
170,356 shs
Market Capitalization
$83.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33

Passage Bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
640.7% Upside
$11.33 Price Target
Short Interest
Healthy
1.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.89mentions of Passage Bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$10,898 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.49) to ($1.92) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.05 out of 5 stars

Medical Sector

10th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

3rd out of 170 stocks

See Top Rated MarketRank™ Stocks Here

PASG stock logo

About Passage Bio (NASDAQ:PASG) Stock

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Receive PASG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter.

PASG Stock News Headlines

January 27, 2023 | americanbankingnews.com
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $11.33
January 24, 2023 | msn.com
‘Passages’ Sundance Film Review: Ira Sachs’ Polyamorous Drama Excites & Frustrates
January 27, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 20, 2023 | finance.yahoo.com
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 7, 2023 | finance.yahoo.com
After losing 67% in the past year, Passage Bio, Inc. (NASDAQ:PASG) institutional owners must be relieved by the recent gain
December 15, 2022 | markets.businessinsider.com
Expert Ratings for Passage Bio
December 14, 2022 | finance.yahoo.com
Passage Bio Stock Jumps After Gene Therapy Study In Lysosomal Storage Disorder
December 14, 2022 | msn.com
Passage Bio posts early Phase 1/2 data for lysosomal storage disease drug
January 27, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 14, 2022 | markets.businessinsider.com
Passage Bio Says New Interim Data From Imagine-1 Clinical Study Strengthens Safety Profile Of PBGM01
December 14, 2022 | finance.yahoo.com
Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study
November 21, 2022 | finance.yahoo.com
Estimating The Fair Value Of Passage Bio, Inc. (NASDAQ:PASG)
November 10, 2022 | bizjournals.com
Philadelphia gene therapy developer Passage Bio trims workforce by another 23%
November 10, 2022 | finance.yahoo.com
Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 8, 2022 | finance.yahoo.com
Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day
November 3, 2022 | finance.yahoo.com
Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022
October 11, 2022 | finance.yahoo.com
Here's Why Passage Bio (NASDAQ:PASG) Must Use Its Cash Wisely
October 10, 2022 | bizjournals.com
Philadelphia gene therapy developer Passage Bio names former Novartis executive as new CEO
October 10, 2022 | nasdaq.com
Passage Bio Names William Chou CEO With Immediate Effect - Quick Facts
October 10, 2022 | marketwatch.com
Passage Bio Names William Chou CEO >PASG
October 10, 2022 | finance.yahoo.com
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
September 26, 2022 | finance.yahoo.com
Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 7, 2022 | benzinga.com
Newman Ferrara LLP Announces Corporate Governance Investigations of Passage Bio, Inc. (PASG)
August 11, 2022 | msn.com
Passage Bio Commences Initial-Stage Brain Disorder Study
August 5, 2022 | finance.yahoo.com
Passage Bio to Present at 2022 Wedbush PacGrow Healthcare Virtual Conference
August 4, 2022 | msn.com
Passage Bio: Q2 Earnings Insights
August 4, 2022 | finance.yahoo.com
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
See More Headlines
Receive PASG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter.

PASG Company Calendar

Last Earnings
11/10/2022
Today
1/27/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PASG
CUSIP
N/A
CIK
1787297
Web
www.passagebio.com
Phone
267-866-0311
Fax
N/A
Employees
133
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.33
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+640.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-185,390,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-59.38%
Return on Assets
-50.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.29
Quick Ratio
10.29

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.89 per share
Price / Book
0.26

Miscellaneous

Outstanding Shares
54,553,000
Free Float
46,861,000
Market Cap
$83.47 million
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Dr. William Chou M.D.
    CEO & Director
  • Dr. James M. Wilson M.D. (Age 67)
    Ph.D., Co-Founder & Chief Scientific Advisor
  • Ms. Simona King (Age 50)
    CFO & Corp. Sec.
  • Mr. Alexandros Fotopoulos MBA (Age 53)
    MSc, Chief Technical Officer
    Comp: $400.11k
  • Mr. Stuart M. Henderson
    VP of Corp. Devel. & Investor Relations
  • Mr. Edgar B. Cale Esq. (Age 58)
    J.D., Gen. Counsel & Company Sec.
  • Gregory Fuest
    VP of Global Commercial Strategy & Marketing
  • Dr. Mark Forman M.D. (Age 58)
    Ph.D., Chief Medical Officer
  • Desiree Luthman D.D.S.
    Sr. VP of Global Regulatory Affairs
  • David Weinstein M.D.
    Sr. VP of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PASG Stock - Frequently Asked Questions

Should I buy or sell Passage Bio stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Passage Bio in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PASG shares.
View PASG analyst ratings or view top-rated stocks.

What is Passage Bio's stock price forecast for 2023?

8 brokers have issued 1-year price targets for Passage Bio's shares. Their PASG share price forecasts range from $5.00 to $24.00. On average, they expect the company's stock price to reach $11.33 in the next twelve months. This suggests a possible upside of 640.7% from the stock's current price.
View analysts price targets for PASG or view top-rated stocks among Wall Street analysts.

How have PASG shares performed in 2023?

Passage Bio's stock was trading at $1.38 at the beginning of 2023. Since then, PASG stock has increased by 10.9% and is now trading at $1.53.
View the best growth stocks for 2023 here.

When is Passage Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our PASG earnings forecast.

How were Passage Bio's earnings last quarter?

Passage Bio, Inc. (NASDAQ:PASG) announced its earnings results on Thursday, November, 10th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.26.

What other stocks do shareholders of Passage Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Passage Bio investors own include Alector (ALEC), NVIDIA (NVDA), Advanced Micro Devices (AMD), DocuSign (DOCU), Intel (INTC), Alteryx (AYX), Gossamer Bio (GOSS), JD.com (JD), Micron Technology (MU) and Black Diamond Therapeutics (BDTX).

When did Passage Bio IPO?

(PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager.

What is Passage Bio's stock symbol?

Passage Bio trades on the NASDAQ under the ticker symbol "PASG."

Who are Passage Bio's major shareholders?

Passage Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Marquette Asset Management LLC (0.12%). Insiders that own company stock include Alexandros Fotopoulos, Athena Countouriotis, Bruce A Goldsmith, Gary Romano, Jill M Quigley, Life Sciences Ix LP Frazier, Orbimed Advisors Llc, Richard Steven Morris, Sandip Kapadia and Thomas Woiwode.
View institutional ownership trends.

How do I buy shares of Passage Bio?

Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Passage Bio's stock price today?

One share of PASG stock can currently be purchased for approximately $1.53.

How much money does Passage Bio make?

Passage Bio (NASDAQ:PASG) has a market capitalization of $83.47 million. The company earns $-185,390,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis.

How many employees does Passage Bio have?

The company employs 133 workers across the globe.

How can I contact Passage Bio?

Passage Bio's mailing address is TWO COMMERCE SQUARE 2001 MARKET STREET 28TH FLOOR, PHILADELPHIA PA, 19103. The official website for the company is www.passagebio.com. The company can be reached via phone at 267-866-0311 or via email at investors@passagebio.com.

This page (NASDAQ:PASG) was last updated on 1/27/2023 by MarketBeat.com Staff